In his latest column for The Wall Street Journal’s Think Tank, Drew Altman discusses new poll findings showing very small numbers of consumers are using provider quality and price information. All previous columns by Drew Altman are available online.
- view as grid
- view as list
Poll Finds Nearly Three Quarters of Americans Say Prescription Drug Costs Are Unreasonable, and Most Blame Drug Makers Rather Than Insurers for the Problem
If Supreme Court’s King v. Burwell Decision Restricts Insurance Subsidies to Certain States, Most Say Congress Should Act to Ensure Residents of All States are Eligible, and a Majority in Potentially Affected States say Their State Should Act Public’s Views on Affordable Care Act Are Divided and Unchanged: 42% Unfavorable…
In this column for The Wall Street Journal’s Think Tank, Drew Altman finds the public’s healthcare priorities have more to do with drug costs and other real world issues people deal with using the health care system than the ongoing partisan wrangling over the Affordable Care Act (ACA).
In his latest column for The Wall Street Journal’s Think Tank, Drew Altman finds the public’s health-care priorities have more to do with drug costs and other real-world issues people deal with using the health-care system than the ongoing partisan wrangling over the Affordable Care Act. All previous columns by Drew Altman are available…
Given recent news about some high-cost prescription drugs and the debate about who should pay for them, this month’s Kaiser Health Tracking Poll has a special focus on the issue. Nearly three-quarters of the public think that the cost of prescription drugs is unreasonable. Americans place much of the blame with the drug companies saying they set prices too high and that company profits are a major factor in drug pricing. The poll also finds that most of the public still hasn’t heard much about the Supreme Court case on whether people in states with federal marketplaces are eligible for financial assistance to purchase health insurance. Most feel that Congress and states should act if the Court rules for the plaintiffs, but there is no agreement among partisans.
USA Today/Kaiser Family Foundation/Harvard School of Public Health Survey: The Public on Prescription Drugs and Pharmaceutical Companies: Toplines
This document provides the detailed toplines from a USA Today/Kaiser/Harvard survey examining Americans’ views on, and experiences with, prescription drugs and the pharmaceutical industry, including drug costs, advertisements, safety issues, government regulation and medical research. Toplines (.pdf)
With renewed discussion of the high cost of prescription drugs recently, the August Kaiser Health Tracking poll finds that most Americans feel that drug costs are unreasonable and that drug companies put profits before people. At the same time, the public largely values the role prescription drug companies play, with most saying that prescription drugs developed in the past two decades have made the lives of people in the U.S. better, including about 4 in 10 who say a lot better. When it comes to their views of the Affordable Care Act (ACA) this month, the American public remains divided in their opinion of the law. Those who favor repeal are divided on whether the law should be replaced with a Republican-sponsored alternative or if it should be repealed and not replaced
Most Say They Can Afford Their Prescription Drugs, But One in Four Say Paying is Difficult, Including More Than Four in Ten People Who are Sick
Large Bipartisan Majorities Support Range of Policy Changes They Believe Would Curb Drug Costs Opinion on the Affordable Care Act Remains Largely Unchanged In August About half of Americans (54%) report currently taking a prescription drug, and a large majority of them (72%) say their prescriptions are very or somewhat…
Kaiser/Harvard National Survey of Americans’ Views on Managed Care-Massachusetts Toplines to National Sample
Kaiser/Harvard National Survey of Americans’ Views on Managed Care-Massachusetts Toplines to National Sample Note: This publication is not available on our website. However, the data from these surveys is still available through the Public Opinion and Media Research Group. Please email firstname.lastname@example.org for more information.